Full Press Release Details
| Appendix 4C Quarterly report for entities | ||||
| admitted on the basis of commitments |
Appendix 4C 3rd Quarter
For Entities Admitted on the Basis of Commitments
Introduced 31/3/2000. Amended 30/9/2001
| Name of Entity: |
| Prima BioMed Ltd (ASX:PRR) |
| ABN: | Quarter Ended ( Current Quarter ) | |||
| 90 009 237 889 | 31 March 2015 |
Consolidated Statement of Cash Flows
| Cash flows related to operating activities | Current Quarter $A 000 | Year-to-Date $A 000 | ||||||
| 1.1 | Receipts from customers | 5,775 | 5,775 | |||||
| 1.2 | Payments for | |||||||
| (a) staff costs | (904) | (2,691) | ||||||
| (b) advertising and marketing | (85) | (234) | ||||||
| (c) research and development | (2,237) | (6,902) | ||||||
| (d) leased assets | - | - | ||||||
| (e) other working capital | (946) | (1,785) | ||||||
| 1.3 | Dividends received | - | - | |||||
| 1.4 | Interest and other items of a similar nature received | 9 | 336 | |||||
| 1.5 | Interest and other costs of finance paid | - | - | |||||
| 1.6 | Income taxes expense | - | - | |||||
| 1.7 | Other (R&D tax refund, grants received) | 793 | 1,174 | |||||
| Net operating cash flows | 2,405 | (4,327) |
+ See chapter 19 for defined terms.
Appendix 4C Quarterly report for entities
admitted on the basis of commitments
| Current Quarter $A 000 | Year-to-Date $A 000 | |||||||
| 1.8 | Net operating cash flows (carried forward) | 2,405 | (4,327) | |||||
| Cash flows related to investing activities | ||||||||
| 1.9 | Payment for acquisition of: | |||||||
| (a) businesses (item 5) | - | (15,796) | ||||||
| (b) equity investments | - | - | ||||||
| (c) intellectual property | - | - | ||||||
| (d) physical non-current assets | - | (46) | ||||||
| (e) other non-current assets | - | - | ||||||
| 1.10 | Proceeds from disposal of: | |||||||
| (a) businesses (item 5) | - | - | ||||||
| (b) equity investments | - | - | ||||||
| (c) intellectual property | - | - | ||||||
| (d) physical non-current assets | - | - | ||||||
| (e) other non-current assets | - | - | ||||||
| 1.11 | Loans to other entities | - | - | |||||
| 1.12 | Loans repaid by other entities | - | - | |||||
| 1.13 | Other (provide details if material) | - | - | |||||
| Net investing cash flows | - | (15,842) | ||||||
| 1.14 | Total operating and investing cash flows | 2,405 | (20,169) | |||||
| Cash flows related to financing activities | ||||||||
| 1.15 | Proceeds from issues of shares, options, etc. | - | 1,364 | |||||
| 1.16 | Transfer of shares | - | - | |||||
| 1.17 | Proceeds from borrowings net finance costs | - | 2,854 | |||||
| 1.18 | Repayment of borrowings | (212) | (212) | |||||
| 1.19 | Dividends paid | - | - | |||||
| 1.20 | Other - capital raising costs | - | (11) | |||||
| Net financing cash flows | (212) | 3,995 | ||||||
| Net increase (decrease) in cash held | 2,193 | (16,174) | ||||||
| 1.21 | Cash at beginning of quarter/year to date | 5,732 | 23,200 | |||||
| 1.22 | Exchange rate adjustments to item 1.21 | 85 | 984 | |||||
| 1.23 | Cash at end of quarter | 8,010 | 8,010 |
+ See chapter 19 for defined terms.
| 30/9/2001 | ||
| Appendix 4C Page 2 |
Appendix 4C Quarterly report for entities
admitted on the basis of commitments
Payments to Directors of the Entity and Associates of the Directors
Payments to Related Entities of the Entity and Associates of the Related Entities
| Current Quarter $A 000 | ||||
| 1.24 | Aggregate amount of payments to the parties included in item 1.2 | 149 | ||
| 1.25 | Aggregate amount of loans to the parties included in item 1.11 | - | ||
| 1.26 | Explanation necessary for an understanding of the transactions | |||
| Directors fees and consulting fees at normal commercial rates |
Non-Cash Financing and Investing Activities
| 2.1 | Details of financing and investing transactions which have had a material effect on consolidated Assets and liabilities but did not involve cash flows | |||
| Issued 15,323,414 ordinary shares in relation to the Bergen funding agreement. | ||||
| 2.2 | Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest |
Financing Facilities Available
necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).
| Amount Available $A 000 | Amount Used $A 000 | |||||
| 3.1 | Loan facilities (*1) | 48,990 | 4,815 | |||
| 3.2 | Credit standby arrangements | - | - |
+ See chapter 19 for defined terms.
| 30/9/2001 | ||
| Appendix 4C Page 3 |
Appendix 4C Quarterly report for entities
admitted on the basis of commitments
Reconciliation of Cash
| Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows. | Current Quarter $A 000 | Previous Quarter $A 000 | ||||
| 4.1 | Cash on hand and at bank | 7,760 | 4,114 | |||
| 4.2 | Deposits at call | - | 318 | |||
| 4.3 | Bank overdraft | - | - | |||
| 4.4 | Other (Term Deposit) | 250 | 1,300 | |||
| Total: Cash at end of quarter (item 1.23) | 8,010 | 5,732 |
Acquisitions and Disposals of Business Entities
| Acquisitions (Item 1.9(a)) | Disposals (Item 1.10(a)) | |||||
| 5.1 | Name of entity | - | - | |||
| 5.2 | Place of incorporation or registration | - | - | |||
| 5.3 | Consideration for acquisition or disposal | - | - | |||
| 5.4 | Total net assets | - | - | |||
| 5.5 | Nature of business | - | - |
Compliance Statement
| Sign Here: | Date: Thursday 16 th April 2015 | |||||
| Company Secretary | ||||||
| Print Name: | Deanne Miller |
+ See chapter 19 for defined terms.
| 30/9/2001 | ||
| Appendix 4C Page 4 |
Appendix 4C Quarterly report for entities
admitted on the basis of commitments
| 6.2 | - reconciliation of cash flows arising from operating activities to operating profit or loss | |||
| 9.2 | - itemised disclosure relating to acquisitions | |||
| 9.4 | - itemised disclosure relating to disposals | |||
| 12.1(a) | - policy for classification of cash items | |||
| 12.3 | - disclosure of restrictions on use of cash | |||
| 13.1 | - comparative information |
+ See chapter 19 for defined terms.
| 30/9/2001 | ||
| Appendix 4C Page 5 |